研報掘金|中金:對友邦保險去年業績持樂觀態度 維持“跑贏行業”評級
中金公司發報吿表示,對友邦保險2023年全年業績持樂觀態度,維持其“跑贏行業”的評級,目標價94港元,對應2024年預測P/EV為1.8倍,較當前股價有50%的上升空間。中金預計友邦去年按實際匯率計算的新業務價值(VONB)按年增長30.8%至40.4億美元,預計在固定匯率下的VONB增長更為強勁,達到33%。儘管除税後經營溢利(OPAT)按年略為下跌1.4%,但每股股息預計將按年增長2%。內地市場方面,儘管第四季度因定價利率調整而出現短期疲軟,但預計2024年第一季度將實現低雙位數的正增長。友邦在重疾險銷售預計將持續增長,且表現好於同行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.